Anticalins are novel, next generation therapeutic proteins designed to bind and antagonize a wide spectrum of ligands.
They derived from human lipocalins, designed to solve the pharmacological and pharmaceutical limitations of both protein- and non-protein-based drug platforms.
The Consortium will develop, manufacture and clinically test an Anticalin specific for hepcidin, a small iron homeostasis regulating peptide circulating in human blood, which is a key target for the treatment of multiple types of anemia.